Liminatus Pharma, Inc. Class A Common Stock (LIMN) · Fundamental Indicators · Sponda

SPONDAFor value investors

Share

A tool by Poema Parceria de Investimentos

Poema cumulative return: 339,17% vs Ibovespa: 185,64% (jan/2017–jun/2026).
Past results do not guarantee future returns.We seek partners with a long-term vision.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) · Fundamental Indicators · Sponda